A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT01770951 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2023-08-18
Summary
The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.
Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsors & Collaborators
-
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-08-31
- Primary Completion
- 2010-11-30
- Completion
- 2010-11-30
Countries
- United States
- Austria
- Canada
- France
- Germany
- Netherlands
- Spain
- Switzerland
Study Locations
More Related Trials
-
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
NCT00844844 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
NCT01194973 ·Status: COMPLETED ·Phase: PHASE2
-
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183 ·Status: RECRUITING
-
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
NCT05876351 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT02614898 ·Status: TERMINATED
-
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
NCT00844428 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT02949128 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)
NCT04859608 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT03131219 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04861259 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea
NCT05405777 ·Status: COMPLETED
-
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
NCT07308574 ·Status: RECRUITING ·Phase: PHASE4
-
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
NCT03205995 ·Status: TERMINATED ·Phase: PHASE3
-
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
NCT05684159 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
NCT05795140 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT00122304 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04958265 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
NCT05726916 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
NCT03303313 ·Status: WITHDRAWN ·Phase: PHASE2
-
Observational Study of Elizaria® in aHUS Patients
NCT04749810 ·Status: COMPLETED
-
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT01194804 ·Status: COMPLETED ·Phase: PHASE2
-
Complement Inhibition in aHUS Dialysis Patients
NCT02464891 ·Status: TERMINATED ·Phase: PHASE2
-
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05510115 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
NCT05805202 ·Status: RECRUITING ·Phase: NA
-
Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT00122330 ·Status: COMPLETED ·Phase: PHASE3